Year 2023 / Volume 115 / Number 6
Original
Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis

294-300

DOI: 10.17235/reed.2022.9228/2022

Haiying Gong, Di Han, Sen Liu, Chengjiang Liu, Xiaolin Zhu, Diping Chen,

Abstract
Background and aims: vonoprazan, a novel potassium-competitive acid blocking agent, has better clinical outcomes in the treatment of acid-related diseases. However, some adverse events have been associated with vonoprazan for the treatment of acid-associated diseases. Therefore, this systematic review and meta-analysis aimed to explore the safety and tolerability of vonoprazan for acid-associated diseases. Methods: electronic databases were retrieved to determine randomized controlled trials (RCTs) of vonoprazan for acid-associated diseases with any adverse effects and discontinuation. Results: this systematic review and meta-analysis conforming to the selection criteria included 18 RCTs with a total of 7,932 participants. Compared with proton pump inhibitors, oral vonoprazan treatment showed no significant increase in the incidence of adverse effects (95 % CI = 0.987-1.095, p = 0.141). Diarrhea or loose stools analysis showed that there was a statistically significant difference between vonoprazan and proton pump inhibitors (PPIs) treatment (95 % CI = 0.661-0.966, p = 0.021). However, there was no significant difference in constipation, rash or eruption, nausea or vomiting, bloating or abdominal pain, dysgeusia, nasopharyngitis, neurological disorders, upper respiratory tract infection and abnormal investigations between vonoprazan and PPIs treatment. Conclusion: vonoprazan, which has better tolerability and safety, may significantly decrease diarrhea and loose stools in acid-related patients compared with PPIs. Our meta-analysis led to safer strategies for treating acid-related diseases. More high-quality studies with larger sample sizes are needed to further elucidate its efficacy and safety.
Share Button
New comment
Comments
No comments for this article
Related articles

Editorial

Safe use of proton-pump inhibitors

DOI: 10.17235/reed.2023.9834/2023

Citation tools
Gong H, Han D, Liu S, Liu C, Zhu X, Chen D, et all. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. 9228/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1026 visits.
This article has been downloaded 260 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 25/09/2022

Accepted: 28/10/2022

Online First: 10/11/2022

Published: 06/06/2023

Article revision time: 21 days

Article Online First time: 46 days

Article editing time: 254 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology